Samsung Epis Holdings Formed to Propel Growth for Samsung Bioepis and a New Subsidiary

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 03 2025

0mins

Source: Yahoo Finance

Samsung Epis Holdings Establishment: Samsung Epis Holdings Co., Ltd. will be listed on the Korea Exchange (KRX) on November 24, 2025, following the spin-off of Samsung Bioepis from Samsung Biologics, with a focus on biotechnology investment and growth.
Leadership and Strategy: Kyung-Ah Kim will serve as President and CEO of both Samsung Epis Holdings and Samsung Bioepis, emphasizing a commitment to scientific innovation and the development of next-generation therapeutic technologies.
Subsidiary Focus: A new subsidiary under Samsung Epis Holdings will concentrate on developing next-generation biotechnology platforms and drug candidates, aiming to drive innovation beyond the existing biosimilar business.
Samsung Bioepis Operations: Samsung Bioepis will continue its core operations in biosimilars, with plans to strengthen its development capabilities and expand its portfolio to over 20 biosimilars, addressing various therapeutic areas to meet patient needs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Samsung Epis Holdings Formed to Propel Growth for Samsung Bioepis and a New Subsidiary

About the author

Top News

Fed Cuts Interest Rates Amid Economic Concerns

SpaceX Targets $800 Billion Valuation in Secondary Sale

U.S. Consumer Sentiment Slightly Improves in December

U.S. Consumer Spending Slows in September

Related Articles

Caesars Partners with Rampart Casino to Launch Sportsbook in Summerlin by 2026

Luminar Sells Semiconductor Subsidiary for $110 Million to QCi

People Also Watch